Decoy Therapeutics Inc. DCOY
0.87 USD -0.01 (-1.13%)
Regular-session close
0.87 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
0.8407 Day range 0.911
0.835 52-week range 16.92
- YTD
- -88.83%
- 1 year
- -90.77%
News
globenewswire.com Decoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough Awards CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), today announced it has been named…
globenewswire.com Decoy Therapeutics Provides Third Quarter 2026 Business Update Lead pan-coronavirus program expected to file CTA/IND in 2H 2027 Optimized lead candidate shows potential for once-weekly dosing in preclinical studies Cash on balance sheet of $8.1 million at…
globenewswire.com Decoy Therapeutics to Present at The Small Cap Showcase CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York
prnewswire.com Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program Once-Weekly Intranasal Potential : Preclinical PK data demonstrate single-dose drug levels sustained above designed therapeutic concentrations for up to 7 days in nasal mucosal and lung tissue.…
prnewswire.com Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026 announcing the…
prnewswire.com Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of…
prnewswire.com Decoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility CAMBRIDGE, Mass., Sept. 22, 2026…
newsfilecorp.com Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference Rick Pierce, Chief Executive Officer, to deliver an investor presentation on Thursday, September 10 in New York Cambridge, Massachusetts--(Newsfile Corp. - September 8, 2026) - Decoy Therapeutics,…
prnewswire.com Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the…
prnewswire.com Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparedness CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy…
prnewswire.com Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals…
benzinga.com Decoy Stock Rises After Announcing Up to $21 Million Private Placement Financing Decoy Therapeutics Inc. (NASDAQ:DCOY) shares are trading higher. The company announced a $21 million private placement financing with a healthcare investor at $5.91 per share.
gurufocus.com Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing PR Newswire HOUSTON, June 26, 2
prnewswire.com Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of…
prnewswire.com Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- Decoy…
prnewswire.com Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals…
proactiveinvestors.co.uk hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker hVIVO PLC's (AIM:HVO) consultancy contract with Decoy Therapeutics, announced on Monday, is a small deal by any financial measure, but Peel Hunt's reading of it points to something more strategically…
proactiveinvestors.co.uk hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics hVIVO PLC (AIM:HVO), the clinical development company specialising in human challenge trials, has signed a consultancy contract with Decoy Therapeutics to support the development of a novel class of…
prnewswire.com Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic CAMBRIDGE, Mass., June…
prnewswire.com Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development NEW YORK and CAMBRIDGE, Mass., May 26, 2026 /PRNewswire/ -- Decoy…
